Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical trials for B-cell malignancies, however, designing CARs for T-cell based disease remain a challenge due to the ...

The adoptive transfer of T cells engineered to express chimeric antigen receptors (CARs) is a promising new approach for treatment of hematological malignancies. However, preclinical reports of ...

在一项新的研究中，来自南卡罗来纳医科大学霍林斯癌症中心的研究人员揭示了如何设计嵌合抗原受体（chimeric antigen receptor, CAR）Treg细胞的新规则。这一突破可能为对抗1型糖尿病等自身免疫性疾病提供更有效的工具。

A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...

Microcap Chimeric Therapeutics (ASX:CHM) has confirmed its receipt of a $4.17 million tax rebate from Canberra for R&D activities. The cell therapy tech developer now sits on a >$4M cash injection ...

Paul Hopper bought 200.00m shares over the last 12 months at an average price of AU$0.008. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on ...

Despite advances in conventional treatment modalities, patients with metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now ...

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer Twenty-eight patients underwent apheresis and received CAR T cells. Sixteen and 12 patients ...